ARCA biopharma, Inc. — 2014 Form 10-K
Filing and period: The supplied filing is ARCA biopharma, Inc.’s annual report for the fiscal year ended December 31, 2014, filed March 19, 2015—not a quarterly report for Q4. The request metadata names Oruka Therapeutics, Inc.; that name does not match the registrant identified in the filing.
Business context
ARCA was a clinical-stage biopharmaceutical company focused on genetically targeted cardiovascular therapies. Its lead candidate, Gencaro (bucindolol), was being tested for atrial fibrillation in patients with heart failure and reduced ejection fraction. The adaptive GENETIC-AF trial compared Gencaro with metoprolol and targeted patients with a specific beta-1 receptor genotype. The company had no approved products or product revenue.
Financial results and liquidity
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $5.625 million | $2.928 million |
| General and administrative expense | $4.068 million | $4.012 million |
| Total operating expenses | $9.693 million | $6.940 million |
| Net loss | $9.689 million | $6.939 million |
| Net loss per share, basic and diluted | $0.47 | $1.04 |
| Net cash used in operating activities | $9.406 million | $5.288 million |
| Cash and cash equivalents at year-end | $15.354 million | $16.756 million |
- Operating expenses rose approximately 40%, principally as GENETIC-AF screening, enrollment, clinical-site, and CRO activity began. Management expected R&D and G&A expenses to increase in 2015.
- Cash declined by $1.402 million in 2014 after $8.023 million of financing cash inflows, including approximately $7.9 million net proceeds from a February 2014 equity offering.
- At December 31, 2014, total assets were $16.132 million, total liabilities $1.391 million, and stockholders’ equity $14.741 million. The company reported no debt outstanding.
- Current assets were $15.488 million versus current liabilities of $1.388 million. The filing does not present a defined margin measure; with no revenue, operating margins are not meaningful.
Changes, outlook, risks and unusual items
- Clinical timing: Enrollment was below original expectations. Protocol amendments in March 2015 broadened eligibility; management projected completion of the approximately 200-patient Phase 2B enrollment by year-end 2016 and a DSMB interim analysis in the first half of 2017. The company cautioned that the amendments’ effect and timeline were uncertain. Phase 3 would require an additional approximately 420 patients and sufficient financing.
- Funding and going concern: Management and KPMG identified substantial doubt about the company’s ability to continue as a going concern because additional capital or a strategic transaction was necessary. Management expected year-end 2014 cash to fund operations through the end of 2015 at its projected cost structure, but said additional funding would be required before Phase 2B completion. Further equity financing could dilute shareholders; debt could be senior to equity and impose operating covenants.
- Listing risk: Nasdaq notified the company in February 2015 of potential delisting for failing to meet the $1.00 minimum bid-price requirement. The filing reported a March 17, 2015 share price of $0.77 and described a 180-day compliance period.
- Regulatory and commercial uncertainty: Gencaro and its companion genetic test were unapproved. A prior heart-failure NDA received an FDA Complete Response Letter in 2009. The new indication depends on successful clinical results and regulatory review; the diagnostic may require separate FDA approval or clearance. ARCA also lacked the resources to commercialize the drug independently and anticipated needing a partner or substantial additional capital.
- Trial evidence: Management cited retrospective BEST-trial analyses, including a reported 41% reduction in new-onset AF risk overall and 74% in the targeted genotype group. These were prior-study analyses, not results from GENETIC-AF, and should not be treated as prospective confirmation.
- Other assets and obligations: ARCA was exploring development or partnering options for rNAPc2, which received FDA orphan-drug designation for potential Ebola post-exposure treatment; no efficacy or revenue was reported. Gencaro licensing terms include an $8 million milestone upon U.S. approval and royalties of 12.5%–25% of related product revenue, with possible royalty buy-down provisions.
- Audit and controls: KPMG issued an unqualified opinion on the financial statements while highlighting the going-concern uncertainty. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-controls attestation.
Important facts for investors to verify
- Whether the 2015 cash runway assumptions held and whether ARCA obtained financing or a strategic transaction on acceptable terms.
- Actual GENETIC-AF enrollment progress, protocol effects, safety findings, and the DSMB’s Phase 2B recommendation and timing.
- Whether Nasdaq bid-price compliance was regained and whether any reverse split or other listing action occurred.
- FDA requirements and approval prospects for both Gencaro and the companion diagnostic, including implications of the prior Complete Response Letter.
- Potential dilution from future financing and outstanding warrants; the filing reported approximately 9.37 million warrants outstanding at December 31, 2014.